The JPIAMR has been established. The main aim is to develop scientific proposals which will lead to sustainable use of antibiotics to treat infectious diseases and to a decrease in the number of patients with resistant infections in Europe.
The JPIAMR has launched the second transnational call for proposals for research projects on Antimicrobial Resistance. Deadline for pre-proposal applications was 12 May 2015. Nine countries are participating in this call for proposals: Argentina, Belgium, France, Germany, Italy, the Netherlands, Norway, Poland and Sweden.
In total JPIAMR received 16 pre-proposal applications. Dutch organisations are involved in 10 of the applications.
The goal of this call for proposals is to sustain defense against antimicrobial resistance by reviving Neglected and Disused Antibiotics (ND-AB), designing combinations of ND-AB and antibiotic and also designing combinations of ND-AB and non-antibiotic in order to reduce occurrence of resistance or overcome established resistance. The objectives of the call are to repurpose ND-AB and/or identify, characterize and understand interaction between ND-AB and other antibiotics or non-antibiotics used already in the medical setting.
More information on the website of JPIAMR
Seven projects started in early 2015. Dutch researchers are involved in 3 of these projects. The projects are entitled: NAPCLI (coordinator France), noTBsec (coordinator VUmc ) and Rebel (coordinator WUR).
The subject of the 1st call was: InnovaResistance. Innovative approaches to address antimicrobial resistance. The primary aim of this call was to combine the resources, infrastructures, and research strengths of multiple countries/regions in order to overcome antibiotic resistance. The goal is to foster multinational translational research collaborations that can accomplish more than individual countries working independently, leading to improved control of bacterial infections. The 12 countries that participated in this call were Belgium, Canada, Denmark, France, Israel, Norway, Poland, Spain, Sweden, United Kingdom, Turkey and the Netherlands.
In April 2014 the Strategic Research Agenda (SRA) was launched in Brussels (Belgium). ZonMw was responsible for the development of the strategic research agenda (SRA), and keeping the SRA up to date in close collaboration with the Scientific Advisory Board of Joint Programming Initiative on Antimicrobial Resistance (JPIAMR).
Six priorities were determined for the strategic research agenda (SRA) of the JPIAMR. The 6 priorities are:
These topics will give the fight against antimicrobial resistance the multidimensional approach needed to tackle the problem from all angles.
'The SRA should deliver innovative and new approaches to make sure that we can still treat bacterial infections successfully with antibiotics in the 21st century,' says Herman Goossens, chair of JPIAMR Scientific Advisory Board.
Mats Ulfendahl, chair of JPIAMR management board, elaborates: 'The topics and their research activities are a matter of urgency for Europe and reinforce Europe’s contribution to global health; have high expected returns on investment; are complementary to each other and existing research programmes; and have clear links and synergies within and across themes.'